Prof Dr Christof von Kalle Appointed Director of LCTR

A visionary leader to propel Luxembourg’s translational research to new heights

• Luxembourg Clinical and Translational Research Centre (LCTR)

The Luxembourg Institute of Health (LIH) proudly welcomes Prof Dr Christof von Kalle as the new Director of the Luxembourg Center for Translational Research (LCTR) Fuerschungsklinik Lëtzebuerg, effective December 1, 2024.

The Luxembourg Institute of Health (LIH) is delighted to announce the appointment of Prof Dr Christof von Kalle as the Director of the Luxembourg Center for Translational Research (LCTR) – Fuerschungsklinik Lëtzebuerg. With a distinguished career spanning translational oncology, gene therapy, and molecular medicine, Prof Dr von Kalle brings exceptional leadership and expertise to the institute.

Previously the Founding Director of the Charité and Berlin Institute of Health Clinical Study Center, Prof Dr von Kalle is well-versed in fostering collaboration across academia, healthcare, and industry. His leadership will be pivotal in driving the LCTR’s mission to bridge research and clinical care, focusing on chronic diseases such as cancer, neurodegenerative disorders, and autoimmune conditions.
Prof Dr von Kalle will lead the LCTR in its mission to deliver innovative research that bridges scientific discovery and patient care. LCTR plays a pivotal role as a national platform that unites clinicians, researchers, and patients to foster cutting-edge clinical studies and transformative healthcare solutions. With its unique approach to digital health and translational medicine, LCTR is positioned to advance precision medicine and improve outcomes for patients in Luxembourg and beyond.

In his new role, Prof Dr von Kalle will focus on expanding LCTR’s research capacity, fostering national and international collaborations, and strengthening the integration of healthcare and clinical research. He brings a wealth of leadership experience and a vision for innovation:

The LCTR represents a remarkable convergence of innovation, collaboration, and patient-centred research. My goal is to ensure that our efforts at LCTR translate directly into improved patient care while positioning Luxembourg as a global leader in translational medicine. Together, we will build on this foundation and explore new frontiers in biomedical science.“

Under Prof Dr von Kalle’s leadership, the LCTR aims to address pressing healthcare challenges, including cancer, neurodegenerative diseases, and autoimmune disorders. By leveraging Luxembourg’s robust translational infrastructure, LCTR will continue to transform research insights into pioneering therapeutic solutions.

We warmly welcome Prof Dr von Kalle and look forward to the exciting advancements ahead for LCTR and Luxembourg’s healthcare ecosystem.